HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

Rhea-AI Summary

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the SVB Securities Virtual Vaccine Forum. The discussion will focus on HIL-214, an investigational VLP-based vaccine targeting norovirus-related acute gastroenteritis. This session is scheduled for August 18, 2022, from 3:00 – 3:50 p.m. EDT, moderated by David Risinger. Norovirus causes an estimated 700 million cases of acute gastroenteritis globally, leading to significant health costs and impacts on vulnerable populations.

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum. HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, HIL-214, will be a topic of discussion.

Fireside chat details:
Date:	Thursday, August 18, 2022
Time:	3:00 – 3:50 p.m. Eastern Daylight Time (EDT)
Moderator:	David Risinger, CFA
HilleVax Participant:	Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer

Please contact your SVB Securities representative to view the session

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
IR@hillevax.com
+1-617-213-5054

 

FAQ

What is HilleVax's role in the SVB Securities Virtual Vaccine Forum?

HilleVax will participate in a fireside chat discussing their investigational vaccine HIL-214 for norovirus-related acute gastroenteritis on August 18, 2022.

What is the timing of HilleVax's fireside chat during the SVB Securities event?

The fireside chat featuring HilleVax is scheduled for August 18, 2022, from 3:00 to 3:50 p.m. Eastern Daylight Time.

Who will represent HilleVax at the Virtual Vaccine Forum?

Robert Hershberg, M.D., Ph.D., Chairman and CEO of HilleVax, will represent the company at the forum.

What is HIL-214 and what is its significance?

HIL-214 is a virus-like particle-based vaccine candidate aimed at preventing moderate-to-severe norovirus-related acute gastroenteritis, addressing a global health issue.

What is the annual global impact of norovirus?

Norovirus is estimated to cause over 700 million cases of acute gastroenteritis and approximately 200,000 deaths annually, resulting in significant health system costs.